(Q35194375)

7 August 2017

1 reference

title

Safety of immunisation and adverse events following vaccination against hepatitis B. (English)

1 reference

7 August 2017

Philippe Duclos

1

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

Expert Opinion on Drug Safety

7 August 2017

published in

1 reference

7 August 2017

volume

2

1 reference

7 August 2017

issue

3

1 reference

7 August 2017

page(s)

225-231

1 reference

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.225

Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.225

Adverse events associated with hepatitis B vaccine in U.S. children less than six years of age, 1993 and 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.225

The timing of immunization affects the development of diabetes in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.225

Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.225

Safety of neonatal hepatitis B vaccine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.225

Hair loss after routine immunizations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.225

Association between type 1 diabetes and Haemophilus influenzae type b vaccination: birth cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.225

No evidence that vaccines cause insulin dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.225

Childhood vaccinations, vaccination timing, and risk of type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.225

No increase in demyelinating diseases after hepatitis B vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.225

Hepatitis B vaccination and the risk of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.225

Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.225

Two episodes of leukoencephalitis associated with recombinant hepatitis B vaccination in a single patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.225

Infections, vaccinations, and the risk of childhood leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.225

Central nervous system disease in patients with macrophagic myofasciitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.225

Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.225

The process of public policy formulation: the case of thimerosal in vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.225

Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.225

School-based hepatitis B vaccination programme and adolescent multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.225

21 January 2018

Identifiers

DOI

10.1517/14740338.2.3.225

1 reference

7 August 2017

1 reference